Drugs / mRNA-1283
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04813796 | Mar 2021 → Jul 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05137236 | Dec 2021 → Mar 2023 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07266558 | Nov 2025 → Jun 2027 expected | COVID-19 | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04813796 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine” PMID 37074202 ↗ Apr 2023 |
| Route | Intramuscular | “2 intramuscular (IM) injections of mRNA-1283” NCT04813796 ↗ |